News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abbott Laboratories (ABT) Humira May Not be Effective in Colitis, FDA Says



8/24/2012 10:58:46 AM

Abbott Laboratories (ABT)’ rheumatoid arthritis drug Humira, the company’s top-selling product, may not be effective in treating ulcerative colitis in patients who don’t respond to conventional therapies, U.S. regulators said. While two trials on Humira’s use for moderate to severe ulcerative colitis met the studies’ goals, Food and Drug Administration staff in a report today questioned the “clinical meaningfulness” of a difference between patients’ reaction to the drug and a placebo. The staff also said limitations to the studies “introduced uncertainty” to the results.

Read at Bloomberg
Read at Reuters
Read at Fox News


comments powered by Disqus
Bloomberg
Reuters
Fox News
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES